Clinical Trial Update: Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 long-term safety extension study of SR57667B in Alzheimer's disease completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SR57667B

Snippet

Sponsor: Sanofi | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED